United Therapeutics Corporation (NASDAQ:UTHR) Stake Lifted by Envestnet Asset Management Inc.

Envestnet Asset Management Inc. increased its stake in United Therapeutics Corporation (NASDAQ:UTHR) by 18.1% in the 1st quarter, HoldingsChannel reports. The fund owned 71,909 shares of the biotechnology company’s stock after acquiring an additional 11,029 shares during the period. Envestnet Asset Management Inc.’s holdings in United Therapeutics were worth $22,167,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in UTHR. Dunhill Financial LLC lifted its position in United Therapeutics by 100.0% in the 4th quarter. Dunhill Financial LLC now owns 100 shares of the biotechnology company’s stock worth $35,000 after buying an additional 50 shares in the last quarter. Sound Income Strategies LLC bought a new position in shares of United Therapeutics during the 1st quarter valued at $49,000. State of Wyoming acquired a new position in United Therapeutics in the 4th quarter valued at $62,000. Curat Global LLC acquired a new position in United Therapeutics in the 1st quarter valued at $63,000. Finally, Millstone Evans Group LLC acquired a new position in United Therapeutics in the 4th quarter valued at $67,000. 94.08% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several analysts have recently weighed in on the stock. Morgan Stanley decreased their target price on shares of United Therapeutics from $348.00 to $328.00 and set an “equal weight” rating on the stock in a research report on Thursday, July 10th. Wall Street Zen downgraded shares of United Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Friday, May 2nd. HC Wainwright reissued a “buy” rating and set a $425.00 price target on shares of United Therapeutics in a report on Monday, May 5th. UBS Group cut their price target on shares of United Therapeutics from $410.00 to $385.00 and set a “buy” rating for the company in a report on Monday, June 30th. Finally, JPMorgan Chase & Co. cut their price target on shares of United Therapeutics from $350.00 to $330.00 and set an “overweight” rating for the company in a report on Tuesday, July 8th. Four research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. According to MarketBeat.com, United Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $383.08.

United Therapeutics Price Performance

NASDAQ:UTHR opened at $293.24 on Wednesday. The firm’s 50 day simple moving average is $300.99 and its 200 day simple moving average is $319.11. United Therapeutics Corporation has a one year low of $266.98 and a one year high of $417.82. The company has a market cap of $13.23 billion, a PE ratio of 11.70, a P/E/G ratio of 6.51 and a beta of 0.53.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings results on Wednesday, April 30th. The biotechnology company reported $6.63 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.29 by $0.34. The firm had revenue of $794.40 million for the quarter, compared to the consensus estimate of $726.82 million. United Therapeutics had a net margin of 40.44% and a return on equity of 19.33%. The company’s revenue for the quarter was up 17.2% on a year-over-year basis. During the same quarter in the previous year, the company earned $6.17 EPS. Equities research analysts expect that United Therapeutics Corporation will post 24.48 EPS for the current year.

Insider Transactions at United Therapeutics

In other news, CFO James Edgemond sold 12,000 shares of the business’s stock in a transaction that occurred on Monday, June 9th. The shares were sold at an average price of $325.37, for a total value of $3,904,440.00. Following the transaction, the chief financial officer owned 8,118 shares in the company, valued at approximately $2,641,353.66. The trade was a 59.65% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Raymond Dwek sold 3,000 shares of United Therapeutics stock in a transaction on Monday, April 21st. The shares were sold at an average price of $285.57, for a total transaction of $856,710.00. Following the completion of the sale, the director owned 1,750 shares of the company’s stock, valued at $499,747.50. This represents a 63.16% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 84,681 shares of company stock worth $25,261,669. Company insiders own 10.30% of the company’s stock.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.